Osteosarcoma
RecruitingCabozantinib Maintenance Therapy vs Best Supportive Care in Osteosarcoma Patients in Complete Remission or with Residual Disease after First‑Line Chemotherapy
Cabozantinib Maintenance Therapy vs Best Supportive Care in Osteosarcoma Patients in Complete Remission or with Residual Disease after First‑Line Chemotherapy
- Disease:Osteosarcoma
- Substances:Cabozantinib
The Netherlands- Participants:0–17 years · 18–64 years · 65+ years
- Substances:Cabozantinib
- Sponsor:Institut Gustave Roussy













